More importantly, the combination of siRNA targeting circNF1 with anti-PD-L1 showed the most pronounced decrease in tumor volume over time, suggesting that circNF1 deletion rendered ESCC cells more sensitive to anti-PD-L1 treatment (Fig. 7B–D). This evidence concerns the gene CD274 and neoplasm.